Continuous treatment with lenalidomide in multiple myeloma: a case report

  • E. Müldür
  • A. Weißmann
  • C. Leitgeb
  • N. Zojer
  • M. Schreder
  • D. Heintel
  • H. Ludwig
Case report

Summary

We present the case of a 72-year-old woman diagnosed with multiple myeloma (MM) in 1992 and treated with lenalidomide plus dexamethasone (LD) as third-line therapy. The patient achieved a complete remission (CR) after 6 cycles of LD treatment, was treated with LD for almost 4 years, and has now been in CR for 5 years. This case illustrates the potential of lenalidomide for continuous treatment in MM, with side effects controllable through tailored patient management including step-wise dose adaptations.

Keywords

Continuous treatment Lenalidomide Multiple myeloma 

References

  1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111: 2516–20, 2008PubMedCrossRefGoogle Scholar
  2. Rajkumar SV. Treatment of myeloma: cure vs. control. Mayo Clin Proc, 83:1142–5, 2008PubMedCrossRefGoogle Scholar
  3. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 78: 21–33, 2003PubMedCrossRefGoogle Scholar
  4. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010. Haematologica, 94: 270–5, 2009PubMedCrossRefGoogle Scholar
  5. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med, 357: 2123–32, 2007PubMedCrossRefGoogle Scholar
  6. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet, 370: 1209–18, 2007PubMedCrossRefGoogle Scholar
  7. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 352: 2487–98, 2005PubMedCrossRefGoogle Scholar
  8. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med, 357: 2133–42, 2007PubMedCrossRefGoogle Scholar
  9. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia, 23: 2147–52, 2009PubMedCrossRefGoogle Scholar
  10. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia, 25(5): 749–60, 2011PubMedCrossRefGoogle Scholar
  11. Dimopoulos MA, Terpos E. Lenalidomide: an update on evidence from clinical trials. Blood Rev, 24: s21–s6, 2010PubMedCrossRefGoogle Scholar
  12. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev, 24(Suppl. 1): S13–9, 2010PubMedCrossRefGoogle Scholar
  13. Zeldis JB, Knight R, Hussein M, Chopra R, Muller G. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci, 1222: 76–82, 2011PubMedCrossRefGoogle Scholar
  14. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 102: 1115–23, 1998PubMedCrossRefGoogle Scholar
  15. San Miguel J, Dimopoulos M, Bravo M, Weber DM. Longer duration of treatment and maintenance of best response with lenalidomide + dexamethasone increases overall survival (OS) in patients with relapsed/refractory multiple myeloma (abstract 0949). Haematologica, 94: 382, 2009CrossRefGoogle Scholar
  16. Dimopoulos M, Hussein M, Swern A, et al. Full dose of lenalidomide for 12 months followed by a lower maintenance dose improves progression-free survival in patients with relapsed/refractory mutiple myeloma (poster). 51st ASH Annual Meeting, New Orleans, Louisiana, USA, 5–8 December 2009.Google Scholar
  17. San Miguel J, Dimopoulos M, Weber D, Olesnyckyj M. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 Sub-Analysis) (abstract 2712). Annual Meeting of the American Society of Hematology (ASH), Atlanta, Georgia 2007Google Scholar
  18. Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica, 95: 1738–44, 2010PubMedCrossRefGoogle Scholar
  19. Ishak J, Dimopoulos M, Weber D, et al. Declining rates of adverse events and dose modifications with lenalidomide in combintion with dexamethasone (abstract 3708). ASH Annual Meeting Abstracts Blood, 2008Google Scholar
  20. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med, 283: 1121–5, 1970PubMedCrossRefGoogle Scholar
  21. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer, 55: 523–9, 1987PubMedCrossRefGoogle Scholar
  22. Dores GM, Cote TR, Travis LB. New Malignanacies Following Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Myeloma. In: Curtis R, Freedman D, Ron E, Ries R, Hacker D, Edwards G, et al., editors. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000. Bethesda, MD: National Cancer Institute; 2006Google Scholar
  23. Attal M, Cances Lauwers V, Marit G, et al. Lenalidomide maintenance after autologous transplantation for myeloma: a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 2005-02 trial). 13th Biennial International Myeloma Workshop, Paris, France, 3–6 May 2011Google Scholar
  24. Palumbo A, Bringhen S, Zweegman S, et al. Secondary malignancy in elderly myeloma patients. 13th Biennial International Myeloma Workshop, Paris, France, 3–6 May 2011Google Scholar
  25. McCarthy P. A Phase III randomized, double-blind study of maintenance therapy with lenalidomide (CC 5013) or placebo following autologous stem cell transplantation for multiple myeloma. 13th Biennial International Myeloma Workshop, Paris, France, 3–6 May 2011Google Scholar
  26. Dimopoulos M, Weber D, Richardson P, et al. Lenalidomide and dexamethasone (LEN + DEX) treatment in relapsed/refractory multiple myeloma patients does not increase the risk of second primary malignancies (SPM): Analysis of MM-009/010. 16th Congress of the European Hematology Association (EHA), London, England, 9–12 June 2011Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • E. Müldür
    • 1
  • A. Weißmann
    • 1
  • C. Leitgeb
    • 1
  • N. Zojer
    • 1
  • M. Schreder
    • 1
  • D. Heintel
    • 1
  • H. Ludwig
    • 1
  1. 1.Department of Medicine ICenter for Oncology and Hematology, WilhelminenspitalViennaAustria

Personalised recommendations